BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Juillerat P, Christen-Zäch S, Troillet FX, Gallot-Lavallée S, Pannizzon RG, Michetti P. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology. 2007;215:245-251. [PMID: 17823524 DOI: 10.1159/000106584] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Donmez S, Pamuk ON, Gedik M, A K R, Bulut G. A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab. Int J Rheum Dis 2014;17:471-5. [PMID: 24460826 DOI: 10.1111/1756-185X.12274] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 3.1] [Reference Citation Analysis]
2 Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther. 2013;38:563-572. [PMID: 23914999 DOI: 10.1111/apt.12431] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
3 Shareef MS, Munro LR, Owen RG, Highet AS. Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum. Clin Exp Dermatol 2012;37:146-8. [PMID: 22103549 DOI: 10.1111/j.1365-2230.2011.04219.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jaimes-López N, Molina V, Arroyave JE, Vasquez LA, Ruiz AC, Castaño R, Ruiz MH. Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Rep 2009;3:20-3. [PMID: 21886723 DOI: 10.3315/jdcr.2009.1027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
5 Thrash B, Patel M, Shah KR, Boland CR, Menter A. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013;68:211.e1-e33; quiz 244-246. [PMID: 23317981 DOI: 10.1016/j.jaad.2012.10.036] [Cited by in Crossref: 73] [Cited by in F6Publishing: 42] [Article Influence: 9.1] [Reference Citation Analysis]
6 Sehgal R, Stratman EJ, Cutlan JE. Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience. Clin Med Res 2018;16:41-6. [PMID: 29610119 DOI: 10.3121/cmr.2017.1364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Ajili F, Souissi A, Bougrine F, Boussetta N, Abdelhafidh NB, Sayhi S, Louzir B, Doss N, Laabidi J, Othmani S. Coexistence of pyoderma gangrenosum and sweet's syndrome in a patient with ulcerative colitis. Pan Afr Med J 2015;21:151. [PMID: 26327988 DOI: 10.11604/pamj.2015.21.151.6364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
8 Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, Vader JP, Michetti P. Extraintestinal manifestations of Crohn's disease. Digestion. 2007;76:141-148. [PMID: 18239406 DOI: 10.1159/000111029] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
9 Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:1982-1992. [PMID: 26154136 DOI: 10.1097/mib.0000000000000392] [Cited by in Crossref: 256] [Cited by in F6Publishing: 90] [Article Influence: 51.2] [Reference Citation Analysis]
10 Ermis F, Ozdil S, Akyüz F, Pinarbasi B, Mungan Z. Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis: . Inflammatory Bowel Diseases 2008;14:1611-3. [DOI: 10.1002/ibd.20481] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
11 Defilippis E, Feldman S, Huang W. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol 2015;172:1487-97. [DOI: 10.1111/bjd.13493] [Cited by in Crossref: 57] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
12 Kirsner RS. Biological agents for chronic wounds. Am J Clin Dermatol 2010;11 Suppl 1:23-5. [PMID: 20586502 DOI: 10.2165/1153417-S0-000000000-00000] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 McKenzie F, Cash D, Gupta A, Cummings LW, Ortega-Loayza AG. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat 2019;30:264-76. [PMID: 30051737 DOI: 10.1080/09546634.2018.1506083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
14 . Response to Infliximab in Atypical Pyoderma Gangrenosum Associated With Ulcerative Colitis. The American Journal of Gastroenterology 2008;103:2951-2. [DOI: 10.1111/j.1572-0241.2008.02094_14.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
15 Yamamoto T. Pyoderma gangrenosum: An important dermatologic condition occasionally associated with rheumatic diseases. WJR 2015;5:101. [DOI: 10.5499/wjr.v5.i2.101] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Seo HI, Lee HJ, Han KH. Hyperbaric oxygen therapy for pyoderma gangrenosum associated with ulcerative colitis. Intest Res 2018;16:155-7. [PMID: 29422812 DOI: 10.5217/ir.2018.16.1.155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
17 Vaidy K, Winderman R, Rabinowitz SS, Schwarz SM. Treatment of Pyoderma Gangrenosum in Pediatric Inflammatory Bowel Disease. JPGN Reports 2020;1:e008. [DOI: 10.1097/pg9.0000000000000008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study: . Inflammatory Bowel Diseases 2017;23:1174-81. [DOI: 10.1097/mib.0000000000001109] [Cited by in Crossref: 40] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
19 Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199-1201. [PMID: 19673875 DOI: 10.1111/j.1365-2133.2009.09404.x] [Cited by in Crossref: 151] [Cited by in F6Publishing: 114] [Article Influence: 12.6] [Reference Citation Analysis]
20 Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585-595. [PMID: 23835489 DOI: 10.1038/nrgastro.2013.117] [Cited by in Crossref: 124] [Cited by in F6Publishing: 104] [Article Influence: 15.5] [Reference Citation Analysis]
21 Ben Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review. Int Wound J 2019;16:511-21. [PMID: 30604927 DOI: 10.1111/iwj.13067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
22 Cohen PR. Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol 2009;10:301-12. [PMID: 19658442 DOI: 10.2165/11310730-000000000-00000] [Cited by in Crossref: 123] [Cited by in F6Publishing: 73] [Article Influence: 10.3] [Reference Citation Analysis]
23 Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62:646-654. [PMID: 20227580 DOI: 10.1016/j.jaad.2009.05.030] [Cited by in Crossref: 134] [Cited by in F6Publishing: 91] [Article Influence: 12.2] [Reference Citation Analysis]